4-hour Live MOUD Training - 05/02/2026-Presentation Slides - 4-hour Live MOUD Training with Dr. Wyatt

Presentation Slides - 4-hour Live MOUD Training with Dr. Wyatt

Pdf Summary

This 4-hour PCSS-MOUD training by Stephen A. Wyatt, D.O. provided an evidence-based overview of opioid use disorder (OUD) and medications for opioid use disorder (MOUD). It emphasized addiction as a chronic brain disease influenced by genetics, environment, trauma, and social factors, and highlighted the major public health burden of substance use disorders, including overdose deaths, reduced life expectancy, and high economic costs.<br /><br />The course reviewed the three main MOUD options: methadone, buprenorphine, and naltrexone. It explained their pharmacology, safety, dosing, and comparative effectiveness. Buprenorphine was highlighted as a high-affinity partial agonist with a strong safety profile, effective for reducing cravings, withdrawal, illicit opioid use, and overdose risk. Methadone’s effectiveness and risks, including respiratory depression and QTc prolongation, were also covered. Naltrexone’s role as an antagonist was discussed, along with challenges in initiation and adherence.<br /><br />A major section focused on patient evaluation and practical office-based opioid treatment (OBOT). Topics included building a therapeutic alliance, using non-stigmatizing language, screening for co-occurring psychiatric and medical conditions, performing physical exams, urine drug testing, and applying DSM-5 criteria. The training also reviewed induction strategies for buprenorphine, including standard, high-dose, and microdosing approaches, as well as management of precipitated withdrawal.<br /><br />Special populations and specialty topics included co-occurring mental illness, chronic and perioperative pain management, pregnancy and neonatal opioid withdrawal, adolescents, HIV, renal failure, and hepatic dysfunction. The presentation stressed integrated care, continuing MOUD when possible, and coordinating with other clinicians.<br /><br />Overall, the key message was that MOUD saves lives, improves retention in treatment, and reduces opioid-related harm, but access remains limited by stigma, training gaps, insurance barriers, and system constraints.

Keywords

opioid use disorder

medications for opioid use disorder

buprenorphine

methadone

naltrexone

office-based opioid treatment

buprenorphine induction

precipitated withdrawal

stigma reduction

overdose prevention